77 related articles for article (PubMed ID: 15737560)
21. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
23. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.
Beerepoot LV; Witteveen EO; Groenewegen G; Fogler WE; Sim BK; Sidor C; Zonnenberg BA; Schramel F; Gebbink MF; Voest EE
Clin Cancer Res; 2003 Sep; 9(11):4025-33. PubMed ID: 14519623
[TBL] [Abstract][Full Text] [Related]
25. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.
Schöffski P; Breidenbach I; Krauter J; Bolte O; Stadler M; Ganser A; Wilhelm-Ogunbiyi K; Lentzen H
Eur J Cancer; 2005 Jul; 41(10):1431-8. PubMed ID: 15913988
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C
Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
Czuczman MS; Thall A; Witzig TE; Vose JM; Younes A; Emmanouilides C; Miller TP; Moore JO; Leonard JP; Gordon LI; Sweetenham J; Alkuzweny B; Finucane DM; Leigh BR
J Clin Oncol; 2005 Jul; 23(19):4390-8. PubMed ID: 15994148
[TBL] [Abstract][Full Text] [Related]
28. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS
J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406
[TBL] [Abstract][Full Text] [Related]
29. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).
Bergmann L; Aamdal S; Marreaud S; Lacombe D; Herold M; Yamaguchi T; Wilhelm-Ogunbiyi K; Lentzen H; Zwierzina H;
Eur J Cancer; 2008 Aug; 44(12):1657-62. PubMed ID: 18602257
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
[TBL] [Abstract][Full Text] [Related]
32. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
Levine AM; Tulpule A; Quinn DI; Gorospe G; Smith DL; Hornor L; Boswell WD; Espina BM; Groshen SG; Masood R; Gill PS
J Clin Oncol; 2006 Apr; 24(11):1712-9. PubMed ID: 16520466
[TBL] [Abstract][Full Text] [Related]
34. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
Gerber DE; Stopeck AT; Wong L; Rosen LS; Thorpe PE; Shan JS; Ibrahim NK
Clin Cancer Res; 2011 Nov; 17(21):6888-96. PubMed ID: 21989064
[TBL] [Abstract][Full Text] [Related]
35. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Jayson GC; Zweit J; Jackson A; Mulatero C; Julyan P; Ranson M; Broughton L; Wagstaff J; Hakannson L; Groenewegen G; Bailey J; Smith N; Hastings D; Lawrance J; Haroon H; Ward T; McGown AT; Tang M; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
J Natl Cancer Inst; 2002 Oct; 94(19):1484-93. PubMed ID: 12359857
[TBL] [Abstract][Full Text] [Related]
36. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.
Infante JR; Bendell JC; Goff LW; Jones SF; Chan E; Sudo T; Burris HA; Berlin JD
Eur J Cancer; 2013 Apr; 49(6):1169-75. PubMed ID: 23294608
[TBL] [Abstract][Full Text] [Related]
37. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
Brooks D; Taylor C; Dos Santos B; Linden H; Houghton A; Hecht TT; Kornfeld S; Taetle R
Clin Cancer Res; 1995 Nov; 1(11):1259-65. PubMed ID: 9815920
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.
Chow FS; Benincosa LJ; Sheth SB; Wilson D; Davis CB; Minthorn EA; Jusko WJ
Clin Pharmacol Ther; 2002 Apr; 71(4):235-45. PubMed ID: 11956506
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15.
Ball ED; Selvaggi K; Hurd D; Herzig R; Clark L; Malley V; Persichetti J; deMagelhaus-Silverman M
Clin Cancer Res; 1995 Sep; 1(9):965-72. PubMed ID: 9816068
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
